Antibe Therapeutics (STU:4B70) ROCE %: -30.17% (As of Dec. 2023)


STU:4B70 Antibe Therapeutics Inc STU:4B70
10 GF Score
Price €2.44
View Full Analysis

What is Antibe Therapeutics ROCE %?

Antibe Therapeutics STU:4B70 10 ROCE % is -30.17% as of Dec. 2023. GuruFocus rates STU:4B70 with a GF Score™ of 10/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Antibe Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -30.17%.

Antibe Therapeutics  (STU:4B70) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Antibe Therapeutics ROCE % Related Terms

Antibe Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Antibe Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibe Therapeutics ROCE % Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -119.56 -201.59 -56.74 -32.13 -24.64

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.13 -18.49 -35.86 -33.37 -30.17
STU:4B70
10GF Score
Antibe Therapeutics Inc STU:4B70
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibe Therapeutics ROCE % Calculation

Antibe Therapeutics's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=-13.163/( ( (63.946 - 3.367) + (48.165 - 1.887) )/ 2 )
=-13.163/( (60.579+46.278)/ 2 )
=-13.163/53.4285
=-24.64 %

Antibe Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-11.512/( ( (41.691 - 1.984) + (38.524 - 1.91) )/ 2 )
=-11.512/( ( 39.707 + 36.614 )/ 2 )
=-11.512/38.1605
=-30.17 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -30.17% mean?
Antibe Therapeutics (STU:4B70) has a ROCE % of -30.17% as of Dec. 2023.
Is Antibe Therapeutics' ROCE % too high?
Antibe Therapeutics' current ROCE % is -30.17%. Overall, Antibe Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Antibe Therapeutics' ROCE % compare to VRTX and REGN?
Antibe Therapeutics' ROCE % of -30.17% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Antibe Therapeutics's current ROCE % is -30.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibe Therapeutics stock overvalued right now?
Antibe Therapeutics (STU:4B70) has a current ROCE % of -30.17%. The current ROCE % is -30.17%. Antibe Therapeutics' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Antibe Therapeutics (STU:4B70), the current ROCE % is -30.17% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Antibe Therapeutics Business Description

Address 15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) platform to develop next-generation therapies to address inflammation arising from a wide range of medical conditions. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Antibe's drug, otenaproxesul, is in development for the treatment of acute and chronic pain. The company's second pipeline drug is a GI-sparing alternative to ketoprofen. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.
10GF Score

Get the complete analysis for STU:4B70

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price